HALO - HALOZYME THERAPEUTICS, INC.
IEX Last Trade
48.02
-0.090 -0.187%
Share volume: 19,502
Last Updated: Fri 27 Dec 2024 08:30:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$48.11
-0.09
-0.19%
Fundamental analysis
79%
Profitability
100%
Dept financing
28%
Liquidity
75%
Performance
71%
Performance
5 Days
1.84%
1 Month
-0.91%
3 Months
-15.69%
6 Months
-6.97%
1 Year
30.16%
2 Year
-15.91%
Key data
Stock price
$48.02
DAY RANGE
$47.56 - $48.22
52 WEEK RANGE
$34.05 - $65.53
52 WEEK CHANGE
$29.95
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Helen I. Torley
Region: US
Website: halozyme.com
Employees: 390
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: halozyme.com
Employees: 390
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)
Recent news